Verona Pharma Announces December 2024 Investor Conference Participation
VRNA 11.19.2024
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore HealthCONx Conference
About Gravity Analytica
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Piper Sandler 36thAnnual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY
7thAnnual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, FL
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website,www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of InvestorRelations and Communications | IR@veronapharma.com |
| Argot Partners(US Investor Enquiries) | Tel: +1-212-600-1902verona@argotpartners.com |
| Ten Bridge CommunicationsInternational / US Media Enquiries | Tel: +1-781-316-4424tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visitwww.veronapharma.com.
